AAN 2011: key themes in the migraine field include rapid-acting drugs and Botox

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Below are the highlights of the conference's coverage of new migraine drugs.

Published By Datamonitor

AAN 2011: new anti-epileptics with novel mechanisms take center stage

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Developments in late-stage pipeline agents for epilepsy were a key talking point at AAN 2011. Below are the highlights of the conference's coverage of new anti-epileptic drugs.

Published By Datamonitor

AAN 2011: promising new Parkinson's treatment options may reduce motor fluctuations

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Developments in late-stage pipeline agents for Parkinson's disease were a key talking point at AAN 2011. Below are the highlights of the conference's coverage of new Parkinson's drugs.

Published By Datamonitor

AAN 2011: recent FDA approvals for niche indications provide a positive tone

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Below are the highlights of the conference's coverage of new drugs for niche neurological indications.

Published By Datamonitor

AAN 2012: BG-12 remains main focus of Biogen's extensive MS portfolio

Biogen used the platform of the 64th American Academy of Neurology Annual Meeting to provide updates on its extensive MS portfolio. Much time was devoted to its Phase III pipeline candidate BG-12, which looks set to be the next agent to enter the market, as well as the presentation of long-term safety data for Tysabri.

Published By Datamonitor

AAN 2012: Novartis presents new data in an attempt to boost confidence in long-term use of Gilenya

In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.

Published By Datamonitor

AAN 2012: pooled data support future use of late-stage MS and epilepsy products

Teva, Eisai, and GlaxoSmithKline all used the opportunity of this year's American Academy of Neurology Annual Meeting to showcase pooled analysis of their late-stage pipeline candidates. While not groundbreaking, the positive data for laquinimod (MS) and perampanel and Potiga (epilepsy) will bolster physician confidence and position the drugs well in their respective markets.

Published By Datamonitor

AAN 2012: research shows value of early disease identification, but caution in treatment is advised

At AAN 2012, Merck Serono presented data from a long-term study showing that early Rebif treatment significantly reduced the clinical progression of multiple sclerosis. However, early intervention should be used cautiously to avoid unnecessary treatment.

Published By Datamonitor

ABB/Schneider: different strokes for different folks

Published By Datamonitor

Abbey National/Bank of Scotland: they've started, but will they finish?

Published By Datamonitor